Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apricoxib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 9/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 2/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA7 | P43166 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.60 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.56 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apricoxib SCHEMBL346028 | 1.00 | CA1 (0.60) | CA1CA2CA9CA12CA7 | |
| SCHEMBL5314130 | 0.90 | CA9 (0.62) | CA1CA2CA9CA12CA7 | |
| SCHEMBL2841663 | 0.88 | PTGS2 (0.60) | CA1CA2CA9CA12CA7 | |
| SCHEMBL347479 | 0.86 | CA1 (0.59) | CA1CA2CA9CA12CA7 | |
| SCHEMBL2463842 | 0.86 | CA1 (0.59) | CA1CA2CA9CA12CA7 | |
| SCHEMBL347020 | 0.84 | PTGS2 (0.58) | CA1CA2CA9CA12CA7 | |
| SCHEMBL13740431 | 0.84 | LMNA (0.48) | — | |
| SCHEMBL5312529 | 0.84 | PTGS2 (0.58) | CA1CA2CA9CA12CA7 | |
| SCHEMBL17920087 | 0.82 | PTGS2 (0.64) | CA1CA2CA9CA12CA7 | |
| SCHEMBL5308912 | 0.82 | PTGS2 (0.64) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130084281-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | TRAGARA PHARMACEUTICALS, INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-8247423-B2 | Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders | TRAGARA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| EP-2170062-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | Tragara Pharmaceuticals, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009009778-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20090017024-A1 | Methods and Compositions for the Treatment of Cancer, Tumors, and Tumor-Related Disorders | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130084281-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | TP53, VHL, TSG101 | PTGS2 565/4885CA1 1526/4885CA2 2781/4885 |
| US-20090017024-A1 | Methods and Compositions for the Treatment of Cancer, Tumors, and Tumor-Related Disorders | TP53, VHL, TSG101 | PTGS2 565/4885CA1 1526/4885CA2 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.